Literature DB >> 921258

In vitro activities of five oral cephalosporins against aerobic pathogenic bacteria.

S Shadomy, G Wagner, M Carver.   

Abstract

Cefaclor (Lilly 99638) and cefatrizine (BL-S640, SK&F 70771) are orally absorbed, broad-spectrum semisynthetic cephalosporins. They were compared in vitro with cephalexin, cephaloglycin, and cepharadine against a variety of aerobic pathogenic bacteria by an agar dilution procedure. Cefaclor and cefatrizine were found to be similar or superior to cephalexin, cephaloglycin, and cephradine in terms of activity against gram-positive cocci other than enterococci. Only cefatrizine demonstrated any potentially useful activity against some susceptible isolates of enterococci. Cefaclor and cefatrizine also were highly active, equally or more so than the other oral cephalosporins, against several gram-negative species including Escherichia coli, Enterobacter aerogenes, and Klebsiella pneumoniae. None of the cephalosporins were particularly active against Enterobacter cloacae. Both cefaclor and cefatrizine were active against Proteus mirabilis; cefatrizine was uniquely active against indolepositive Proteus species.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 921258      PMCID: PMC429985          DOI: 10.1128/AAC.12.5.609

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Comparative inhibitory activity of BL-S640 and two other cephalosporins.

Authors:  E Yourassowsky; E Schoutens; M P Vanderlinden
Journal:  J Antibiot (Tokyo)       Date:  1975-08       Impact factor: 2.649

2.  BL-S 640, a cephalosporin with a broad spectrum of antibacterial activity: properties in vitro.

Authors:  F Leitner; R E Buck; M Misiek; T A Pursiano; K E Price
Journal:  Antimicrob Agents Chemother       Date:  1975-03       Impact factor: 5.191

3.  BL-S640, a cephalosporin with a broad spectrum of antibacterial activity: bioavailability and therapeutic properties in rodents.

Authors:  F Leitner; D R Chisholm; Y H Tsai; G E Wright; R G Deregis; K E Price
Journal:  Antimicrob Agents Chemother       Date:  1975-03       Impact factor: 5.191

4.  Metabolism of (14C) cefaclor, a cephalosporin antibiotic, in three species of laboratory animals.

Authors:  H R Sullivan; S L Due; D L Kau; J F Quay; W Miller
Journal:  Antimicrob Agents Chemother       Date:  1976-10       Impact factor: 5.191

5.  Comparison of in vitro activity of cephalexin, cephradine, and cefaclor.

Authors:  N J Bill; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1977-03       Impact factor: 5.191

6.  In vitro and clinical studies of cefatrizine, a new semisynthetic cephalosporin.

Authors:  R del Busto; E Haas; T Madhaven; K Burch; F Cox; E Fisher; E Quinn; D Pohlod
Journal:  Antimicrob Agents Chemother       Date:  1976-03       Impact factor: 5.191

7.  In vitro activity of BL-s640 against gram-negative bacilli and Staphylococcus aureus compared with activity of four other semisynthetic cephalosporins.

Authors:  A Vuye; J Pijck; H Soep
Journal:  Antimicrob Agents Chemother       Date:  1976-03       Impact factor: 5.191

8.  Laboratory studies with cefatrizine (SK + F 60771), a new broad-spectrum orally-active cephalosporin.

Authors:  P Actor; J V Uri; L Phillips; C S Sachs; J R Guarini; I Zajac; D A Berges; G L Dunn; J R Hoover; J A Weisbach
Journal:  J Antibiot (Tokyo)       Date:  1975-08       Impact factor: 2.649

9.  In vitro evaluation of the new oral cephalosporin cefatrizine: comparison with other cephalosporins.

Authors:  C C Blackwell; E H Freimer; G C Tuke
Journal:  Antimicrob Agents Chemother       Date:  1976-08       Impact factor: 5.191

  9 in total
  12 in total

1.  Saturable rate of cefatrizine absorption after oral administration to humans.

Authors:  B G Reigner; W Couet; J P Guedes; J B Fourtillan; T N Tozer
Journal:  J Pharmacokinet Biopharm       Date:  1990-02

2.  Cefaclor: summary of clinical experience.

Authors:  R B Kammer; L J Short
Journal:  Infection       Date:  1979       Impact factor: 3.553

Review 3.  In vitro antibacterial effects of cephalosporins.

Authors:  J D Williams; F Moosdeen
Journal:  Drugs       Date:  1987       Impact factor: 9.546

4.  Diffusion disk susceptibility testing with cefaclor.

Authors:  S Shadomy; M Carver
Journal:  Antimicrob Agents Chemother       Date:  1978-02       Impact factor: 5.191

5.  Autobac I procedure to assess susceptibility to Cefaclor.

Authors:  D Gröschel; K Mills; R L Hopfer
Journal:  J Clin Microbiol       Date:  1980-06       Impact factor: 5.948

6.  Human intravenous pharmacokinetics and absolute oral bioavailability of cefatrizine.

Authors:  M Pfeffer; R C Gaver; J Ximenez
Journal:  Antimicrob Agents Chemother       Date:  1983-12       Impact factor: 5.191

7.  Pharmacology of cefaclor in normal volunteers and patients with renal failure.

Authors:  J Santoro; B N Agarwal; R Martinelli; N Wenger; M E Levison
Journal:  Antimicrob Agents Chemother       Date:  1978-06       Impact factor: 5.191

8.  [In vitro activity of cefaclor (author's transl)].

Authors:  H Knothe
Journal:  Infection       Date:  1979       Impact factor: 3.553

9.  Comparative antibacterial activity of an arylglycyl oral cephalosporin, LY164846.

Authors:  N X Chin; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

10.  Pharmacological evaluation of cefaclor in volunteers.

Authors:  G R Hodges; C Liu; D R Hinthorn; J L Harms; D L Dworzack
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.